[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
1. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL: Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol; 2010 Aug;34(8):1193-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.
  • Many patients with stage I nonsmall cell lung carcinoma will develop recurrence after surgical excision.
  • Sox2 is a marker of embryonic stem cell pluripotency that is associated with aggressive tumor behavior and is expressed in a subset of lung adenocarcinomas.
  • We hypothesized that Sox2 expression may provide prognostic information in early stage lung adenocarcinomas.
  • We evaluated formalin-fixed, paraffin-embedded tissue from 104 stage I lung adenocarcinomas resected between 1997 and 2000.
  • Sox2 expression was detected in 50% of the cases and was more frequent in tumors from older and male patients but not significantly associated with smoking status, tumor stage, grade, or histologic subtype.
  • Sox2 seems to be an independent predictor of poor outcome in stage I lung adenocarcinomas and may help stratify patients at increased risk for recurrence.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2006 Dec;3(12):e467 [17194181.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5562-9 [18065728.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] J Neurosci Res. 2008 Jun;86(8):1680-93 [18293417.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2846-53 [18539963.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):17969-78 [18456656.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Methods Mol Biol. 2009;472:397-411 [19107445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2824-8 [19196983.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1091-9 [19188679.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2660-7 [19414679.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6386-90 [19808871.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1238-42 [19801978.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):55-61 [19661786.001]
  • [Cites] Am J Pathol. 2010 Feb;176(2):903-13 [20042675.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Semin Surg Oncol. 2003;21(2):74-84 [14508857.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):79-82 [9591638.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2468-77 [9667266.001]
  • [Cites] Dev Dyn. 1998 Dec;213(4):464-75 [9853967.001]
  • [Cites] Ann Thorac Surg. 2006 Jun;81(6):1958-62; discussion 1962 [16731113.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):790-800 [16873561.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):533-8 [16767105.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • (PMID = 20631605.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090578-060010; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / 2P50 CA090578-06; United States / NCI NIH HHS / CA / P50 CA090578-060010
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  • [Other-IDs] NLM/ NIHMS221695; NLM/ PMC2923819
  •  go-up   go-down


2. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K: Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer; 2006 Nov 15;107(10):2468-73
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma.
  • BACKGROUND: [(18)F]Fluoro-2-deoxyglucose uptake on positron emission tomography (FDG-PET) has been frequently used for diagnosis and staging of lung cancer.
  • The prognostic significance of FDG uptake on PET was evaluated in patients with pathologic Stage I lung adenocarcinoma (tumor stages were based on the TNM classification of the International Union Against Cancer).
  • METHODS: Disease-free survival of 98 patients with pathologic Stage I lung adenocarcinoma who were treated by curative resection was examined in relation to sex, age, histologic grade of differentiation, surgical procedure, tumor stage, and FDG uptake measured as the maximum standardized uptake value (SUV).
  • RESULTS: Sixty-three patients were had Stage IA disease and 35 patients had Stage IB disease.
  • Six patients each with Stage IA and Stage IB disease developed disease recurrence after a mean postsurgical follow-up period of 31 months.
  • Ten (20%) of the 51 patients with moderately or poorly differentiated adenocarcinoma developed disease recurrence, compared with 2 (4%) of the 47 patients with well-differentiated adenocarcinoma (P = .056).
  • CONCLUSIONS: FDG uptake appears to be predictive of disease-free survival in patients with Stage I lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036361.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol; 2008 Apr;3(4):386-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
  • Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan.
  • PATIENTS AND METHODS: Eligible patients with locally advanced or metastatic (stage IIIB/IV) or recurrent non-small cell lung cancer, previously treated with chemotherapy, were randomized to receive once-daily oral vandetanib 100, 200, or 300 mg (1:1:1).
  • CONCLUSION: In Japanese patients with advanced non-small cell lung cancer, vandetanib monotherapy (100-300 mg/d) demonstrated antitumor activity with an acceptable safety and tolerability profile.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperidines / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Administration, Oral. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Double-Blind Method. Female. Humans. Japan / epidemiology. Male. Maximum Tolerated Dose. Middle Aged. Mutation / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379357.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


Advertisement
4. Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, Nowicki ER, Mekhail TM, Mason DP, Rice TW, Blackstone EH: Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. Ann Thorac Surg; 2010 Oct;90(4):1067-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung.
  • BACKGROUND: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease.
  • METHODS: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung.
  • CONCLUSIONS: Stage I adenocarcinoma of the lung recurs.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20868788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL: Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol; 2009 Jan 10;27(2):271-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.
  • PURPOSE: Thyroid transcription factor 1 (TTF1) is a transcription factor that regulates the expression of multiple genes involved in lung development.
  • It is preferentially expressed in adenocarcinomas of the lung and has been investigated as a potential prognostic parameter in patients with lung cancer, with conflicting results.
  • TTF1 was consistently expressed in adenocarcinomas (n = 61 and 73; Spearman rho = 0.313 and 0.4 for the first and second set, respectively; P < .0001) independent of their differentiation and stage.
  • Survival analysis showed that patients with stage I adenocarcinoma with TTF1 expression had a longer median overall survival than those without expression (n = 43, 44.3 v 26.2 months, P = .05 for the first cohort; n = 87; 49.7 v 38.5 months, P = .03 for the second cohort) Multivariate analysis revealed an independent lower risk of death for patients with stage I adenocarcinoma with TTF1-expressing tumors (hazard ratio = 0.479, 95% CI, 0.235 to 0.977; P = .043).
  • CONCLUSION: TTF1 expression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of patients with stage I lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


6. Duan Y, Bai LQ: [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jun 16;89(23):1630-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of surgical plus chemotherapy for stage I lung adenocarcinoma].
  • OBJECTIVE: Observe the effect of operation plus post-operative chemotherapy for long-term results of stage I lung adenocarcinoma.
  • METHODS: From January 1994 to January 2005, 427 patients with stage I lung adenocarcinoma underwent surgical resection therapy.
  • The comparison of long-term survival rates was made between post-chemotherapy and surgical resection alone.
  • RESULTS: The analyses disclosed that the stage I a 1, 3, 5 and 10-year survival rate of post-chemotherapy was 100.00%, 92.34%, 86.17% and 74.82%, respectively, while in surgical resection alone was 96.63%, 88.11%, 79.52% and 65.85%, respectively.
  • The stage I b 1, 3, 5 and 10-year survival rate of post-chemotherapy was 96.84%, 77.99%, 69.56% and 64.36%, respectively, while in surgical resection alone was 85.65%, 67.11%, 59.56% and 53.06%, respectively.
  • There was statistically significant difference between 1 year survival rate of stage I a patients with post-chemotherapy and those with surgical resection alone (P < 0.05); 1 year survival rate of stage I b patients with post-chemotherapy and those with surgical resection alone (P < 0.01).
  • CONCLUSION: The operation plus post-operative chemotherapy is better than surgical resection alone in stage I a and I b.
  • Surgical plus post-operative chemotherapy mode is indispensable for better prognosis of stage I a and I b lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957512.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Fan Y, Jiang Y, Chang R, Yao S, Hu P, Qiao Y: [Retrospective analysis of screening results of lung cancer cases among occupational population at high risk of lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Apr 20;10(2):102-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of screening results of lung cancer cases among occupational population at high risk of lung cancer].
  • BACKGROUND: Lung cancer has become the leading cause of the cancer death in China.
  • Population-based lung cancer screening is still in controversy.
  • The objective of this study is to analyze the effect of annual chest radiography and sputum cytological screening conducted in high lung cancer risk population who were exposed to work related carcinogens.
  • METHODS: A retrospective analysis was conducted to evaluate the screening results of the lung cancer cases diagnosed from 1992 to 2001 in the miners of Yunnan tin mine.
  • By December 31, 2001, 433 lung cancer cases had been confirmed, 371 cases out of them had cytological/pathological evidence, and 55.0% were squamous cell carcinoma followed by adenocarcinoma and small cell carcinoma.
  • Stage I or II accounted for 24%.
  • 80.8% of early stage cases had at least one previous positive finding from screening.
  • CONCLUSIONS: Annual lung cancer screening with combination of chest radiography and sputum cytology play some extent role in early detection of lung cancer in high risk population.
  • The results may provide some primary data for lung cancer screening in special population who are at high risk of lung cancer in China.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114930.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Okudela K, Woo T, Mitsui H, Yazawa T, Shimoyamada H, Tajiri M, Ogawa N, Masuda M, Kitamura H: Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease. Int J Clin Exp Pathol; 2010;3(4):348-66
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease.
  • We have established a concise sub-typing system suitable for predicting the postoperative outcome in cases of stage I lung adenocarcinoma (ADC), using morphometric profiling.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 2010 Feb;34(2):243-55 [20061937.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):341-8 [17350137.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):355-62 [19162366.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 20490327.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2872743
  • [Keywords] NOTNLM ; Lung adenocarcinoma / altered sub-typing system / morphometric profiling / prognostic value / stage I
  •  go-up   go-down


9. Ohta S, Hirose M, Ishibashi H, Muro H: [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?]. Kyobu Geka; 2007 Jul;60(7):519-22; discussion 522-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?].
  • OBJECTIVE: This study was done for the purpose of picking out the cases of poor prognosis from the peripherally located stage I adenocarcinoma of the lung.
  • METHODS: Between January 1989 and December 2004, 235 patients with peripherally located stage I adenocarcinoma of the lung were resected curatively in our hospital.
  • The ratio of the cases without ductal invasion was 61% in stage IA, and 31% in stage IB.
  • The 5-year survival rate was 99% in the cases without ductal invasion in stage IA, 100% in the cases without ductal invasion in stage IB, 90% in the cases with ductal invasion in stage IA, and 65% in the cases with ductal invasion in stage IB, respectively.
  • And the 5-year survival rate without recurrence was 94% in the cases without ductal invasion in stage IA, 76% in the cases without ductal invasion in stage IB, 76% in the cases with ductal invasion in stage IA, and 54% in the cases with ductal invasion in stage IB, respectively.
  • CONCLUSIONS: Ductal invasion is significant prognostic factor in stage I adenocarcinoma of the lung.
  • Adjuvant chemotherapy is unnecessary for the case without ductal invasion in stage IA.
  • But we think that adjuvant chemotherapy is necessary for the case with ductal invasion in stage IA and for the case in stage IB, because there is much recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642210.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Cho S, Sung SW, Jheon S, Chung JH: Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis. Lung; 2008 Nov-Dec;186(6):411-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis.
  • STUDY OBJECTIVES: Stage I adenocarcinoma of the lung is the most common type of lung cancer.
  • A better understanding of the histopathology and molecular biology of lung cancer might improve the capability to predict the outcome for any individual patient.
  • The purpose of this study was to evaluate several histopathologic and molecular markers in order to assess their prognostic value in stage I adenocarcinoma.
  • CONCLUSIONS: In resected stage I adenocarcinoma, necrosis, lymphatic vessel invasion, E-cadherin, and p53 have been identified as independent predictors of disease-free survival.
  • [MeSH-major] Adenocarcinoma / pathology. Cadherins / analysis. Ki-67 Antigen / analysis. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836777.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Usami N, Yoshioka H, Mori S, Imaizumi M, Nagasaka T, Ueda Y: Primary lung adenocarcinoma with heterotopic bone formation. Jpn J Thorac Cardiovasc Surg; 2005 Feb;53(2):102-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung adenocarcinoma with heterotopic bone formation.
  • A 46-year-old man was referred to our hospital for the treatment of lung cancer.
  • Since he was diagnosed as having a primary lung adenocarcinoma (clinical stage IB), a left upper lobectomy with mediastinal lymph node dissection was performed.
  • Histologically, the tumor was a poorly differentiated adenocarcinoma with rich fibrous stroma, in which there were island-shaped bone formation lesions.
  • This finding may elucidate a possible mechanism of heterotopic bone formation.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Ossification, Heterotopic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782573.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Morphogenetic Proteins
  •  go-up   go-down


12. Hadzismailović A, Pilav A: Evaluation of the preoperative stage and operative findings in patients with non-small cell lung cancer. Bosn J Basic Med Sci; 2007 Aug;7(3):239-44
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the preoperative stage and operative findings in patients with non-small cell lung cancer.
  • Lung cancer is responsible for 40% mortalities from malignant diseases in man and exhibits an extremely infiltrating way of growing.
  • According to its biological characteristics and response to treatments it may be divided in to small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC), which also includes other histological types.
  • Lung cancer treatment includes surgical treatment, chemotherapy, radiotherapy, the combination of the former three as well as symptomatic treatment.
  • In this study, we analyzed 125 patients with lung cancer, that were hospitalized at the Clinic for Thoracic Surgery in KCU Sarajevo.
  • The results of testing the significance of differences according to the cancer types in non small cell lung cancer were planocellular, adenocarcinoma, and macrocellular.
  • Comparing the preoperative staging and operative findings through stages we obtained to the following results: in stage ST0 the deviation was 16,7%, STIA the deviation was 40,1%, STIB the deviation was 16,1%, STIIA the deviation was 11,1%, STIIB the deviation was 12,5%, STIIIA the deviation was 33,33%, STIIIB the deviation was 33, 3%.
  • From the overall number of patients, who were in preoperatively graded stage STIA, operative findings confirmed STIA, which makes the most important statistically significant difference.
  • In 36 patients or 28,8% the status was changed in operative finding.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848150.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


13. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • Of the initial endoscopic finding available 45 patients, Bormann type III and IV were 23 (51%) and 15 (33%) patients, respectively.
  • Clinically, initial advanced stage was predictive value of poor prognosis (P=0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sanchez A, Provencio M, Artal A, Constenla M, Garcia-Gomez R, Viñolas N, Domine M, Perez FJ, Gayo J: Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient's convenience on day 8 NVBO administration. J Clin Oncol; 2009 May 20;27(15_suppl):e19096

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient's convenience on day 8 NVBO administration.
  • : e19096 Background: Severe neutropenia observed during chemotherapy (CT) is a clinical finding leading to treatment modification and, sometimes, life-threatening events.
  • METHODS: Between October 2007 and September 2008, 31 chemo-naïve p with histologically confirmed stage IIIB/IV NSCLC were included.
  • Patient's characteristics were: Median age, 62 years (range 32-73); males, 93.5%; smokers, 38.7%; all PS 0-1; adenocarcinoma, 33.3% / squamous, 36.7%; stage IIIB, 14.8% / IV, 85.2%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962248.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M, Weber WA: FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin; 2005;44(6):249-55; quiz N55-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding.
  • The clinical importance of a FDG PET finding discordant with CT was determined in patients with locally advanced ADE.
  • RESULTS: When read independently from the CT scan FDG PET indicated a clinically relevant change in tumour stage in 9/40 patients (23%) and a non-relevant change in 11/40 patients (28%).
  • In 4/9 patients PET was incorrect (3 false positive due to suspicion of M1-lymph nodes or lung metastases, 1 false negative in disseminated liver metastases).
  • With concomitant reading, PET indicated a clinically relevant change in tumour stage in 6/40 patients (15%) and a non-relevant change in 5/40 patients (13%).
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400385.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Cadranel J, Lavolé A, Gounant V, Wislez M: [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S158-16S163
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].
  • [Transliterated title] Formes cliniques des cancers thoraciques. Carcinome bronchiolo-alvéolaire (CBA) et adénocarcinome pulmonaire avec composante bronchiolo-alvéolaire (ADC-CBA): un continuum anatomo-clinique.
  • Bronchioloalveolar carcinoma (BAC) is a primary pulmonary adenocarcinoma (ADC) arising in the cells of the terminal respiratory unit.
  • Although stage IIIB and IV tumours were excluded from the strict WHO definition of BAC the first international workshop on this tumour in 2004 emphasised the clinico-pathological continuum that exists between BAC as defined by WHO and ADC with BAC features (ADC-BAC).
  • The high frequency of epidermal growth factor receptor (EGFR) expression and amplification and/or mutation of its gene, as well as the finding in some cases of a major response to EGFR tyrosine-kinase inhibitors, have lead to several therapeutic trials of these drugs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268353.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


17. Husmann L, Tatsugami F, Buechel RR, Pazhenkottil AP, Kaufmann PA: Incidental detection of a pulmonary adenocarcinoma on low-dose computed tomography used for attenuation correction in myocardial perfusion imaging with SPECT. Clin Nucl Med; 2010 Sep;35(9):751-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental detection of a pulmonary adenocarcinoma on low-dose computed tomography used for attenuation correction in myocardial perfusion imaging with SPECT.
  • However, the CT scan used for attenuation correction (AC) demonstrated a large tumor in the right upper lung as an incidental finding, and the patient was referred for staging with F-18 fluorodeoxyglucose positron emission tomography/CT and subsequently to thoracic surgery.
  • The lesion was resected and diagnosed to be an adenocarcinoma (stage pT2, cN0, cM0).
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Incidental Findings. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Myocardial Reperfusion. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706062.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Uña E, Cuadrillero F, López-Lara F: Drug extravasation: a dreaded complication. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old man diagnosed with a stage I lung adenocarcinoma was treated by an upper right lobectomy.
  • Eighteen months later an elevation of carcinoembryoinc antigen (CEA) was detected, and CT tomography revealed a stage IV disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacotherapy. 1999 Aug;19(8):1002-5 [10453974.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):259-60 [10926814.001]
  • [Cites] Ann Plast Surg. 2000 Oct;45(4):438-41 [11037169.001]
  • [Cites] Support Care Cancer. 2001 Mar;9(2):131-4 [11305072.001]
  • [Cites] Anticancer Drugs. 2004 Apr;15(4):401-4 [15057145.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):858-62 [15151940.001]
  • [Cites] Semin Oncol. 2006 Feb;33(1):139-43 [16473651.001]
  • [Cites] Acta Derm Venereol. 2008;88(3):310-1 [18480949.001]
  • [Cites] Semin Oncol. 2006 Feb;33(1):86-97 [16473647.001]
  • [Cites] Ann Pharmacother. 1992 Feb;26(2):263-4 [1554945.001]
  • (PMID = 21686582.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028026
  •  go-up   go-down


19. Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer; 2008 Feb 12;98(3):596-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
  • Although postoperative adjuvant chemotherapy (PAC) with uracil-tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy.
  • We performed comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules.
  • Furthermore, we carried out immunohistochemical studies of 90 adenocarcinoma specimens to validate the results of LC-MS/MS.
  • Cases of adenocarcinoma lacking expression of either myosin IIA or vimentin show a good outcome without PAC, and therefore do not require such treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Lung Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 May 18;105(4):425-31 [11371340.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61 [14519751.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):999-1012 [15195114.001]
  • [Cites] J Pathol. 1996 Oct;180(2):175-80 [8976877.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):483-95 [9033265.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2085-8 [9748123.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Proteomics. 2005 Mar;5(4):856-64 [15668996.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):153-7 [15970650.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Gan. 1979 Apr;70(2):209-14 [381088.001]
  • [Cites] Gan. 1979 Jun;70(3):353-9 [467897.001]
  • [Cites] Oncogene. 1993 Apr;8(4):999-1008 [8455951.001]
  • [Cites] Am J Clin Pathol. 1994 Aug;102(2):171-5 [8042584.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 18212748.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vimentin; 1548R74NSZ / Tegafur; EC 3.6.1.- / Nonmuscle Myosin Type IIA
  • [Other-IDs] NLM/ PMC2243141
  •  go-up   go-down


20. Chen KY, Lee YC, Lai JM, Chang YL, Lee YC, Yu CJ, Huang CY, Yang PC: Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer. Eur J Cancer; 2007 Mar;43(4):782-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer.
  • To find novel prognostic factors, we used the expression profile of a poor prognostic factor of lung cancer, survivin (BIRC5), as a template to search for and compare transcriptome expression profiles in a lung adenocarcinoma microarray dataset.
  • The trophinin expression in lung cancer specimens was examined by immunohistochemical staining.
  • For stage I lung adenocarcinoma, the patients without trophinin expression had a better overall and disease-free survival.
  • Through a combination of data mining and biochemical assays, we identified trophinin, which could enhance cell invasion, as a novel prognostic factor for early stage lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Lung Neoplasms / diagnosis. Microtubule-Associated Proteins / metabolism. Neoplasm Invasiveness / diagnosis. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17254769.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / TRO protein, human
  •  go-up   go-down


21. Sartori G, Bettelli S, Schirosi L, Bigiani N, Maiorana A, Cavazza A, Rossi G: Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. Am J Surg Pathol; 2007 Oct;31(10):1512-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung.
  • We investigated 11 cases of SH by immunohistochemistry, fluorescence in situ hybridization, and polymerase chain reaction-based microsatellite and mutational analyses with particular emphasis on possible alterations of microsatellite loci located at tumor suppressor genes (FHIT, p16, Rb, and p53) involved in lung adenocarcinoma genesis and EGFR, HER2, and K-RAS genes.
  • The finding of microsatellite alterations in chromosomal regions related to genes deeply involved in early stage lung adenocarcinoma could suggest a possible link between SH and bronchioloalveolar carcinoma, but tumor pathway promoted by EGFR, HER2, and K-RAS does not represent a common molecular mechanism of tumorigenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats. Proto-Oncogene Proteins p21(ras) / genetics. Pulmonary Sclerosing Hemangioma / genetics. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics

  • Genetic Alliance. consumer health - Hemangioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895751.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


22. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One; 2009;4(4):e5052
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
  • BACKGROUND: Lung adenocarcinoma is the leading cause of cancer-related deaths among both men and women in the world.
  • Although several well-known markers correlated with poor/metastasis prognosis in lung adenocarcinoma patients by immunohistochemistry was reported, the molecular mechanisms of lung adenocarcinoma development are still not clear.
  • To explore novel molecular markers and their signaling pathways will be crucial for aiding in treatment of lung adenocarcinoma patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary metastatic tumors vs. benign tumors, and a series of invasive cell lines.
  • Among the novel targets identified, FLJ10540 was overexpressed in lung cancer tissues and is associated with cell migration and invasion.
  • Lung adenocarcinoma array profiles and tissue microarray IHC staining data showed that FLJ10540 and VEGF-A, as well as FLJ10540 and phospho-AKT exhibit positive correlations, respectively.
  • Stimulation of lung cancer cells with VEGF-A results in an increase in FLJ10540 protein expression and enhances complex formation with PI3K.
  • CONCLUSIONS/SIGNIFICANCE: This finding set the stage for further testing of FLJ10540 as a new therapeutic target for treating lung cancer and may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in lung cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Cycle Proteins / physiology. Lung Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Nuclear Proteins / physiology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / physiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7 [14641020.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300 [14656735.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):510-8 [15093181.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32592-602 [15145941.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):667-76 [15505410.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):64-8 [9036871.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5223-30 [11431363.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1953-62 [11532975.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32521-7 [9405464.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10002-7 [10187776.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Lung. 2004;182(3):151-62 [15526754.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):477-88 [16198290.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8 [16256070.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):306-14 [16330671.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):480-6 [16170351.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):53-9 [15899546.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23285-95 [16787925.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17(9):3881-96 [16790497.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Feb;8(2):140-9 [17328230.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7758-69 [17178724.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4272-83 [17237822.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Behav Brain Res. 2002 Nov 15;136(2):489-501 [12429412.001]
  • (PMID = 19337377.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cep55 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2659802
  •  go-up   go-down


23. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, Buttitta F, Felicioni L, Nicassio F, Di Fiore PP: Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest; 2007 Nov;117(11):3436-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.
  • Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer deaths in the world.
  • At stage I, the tumor is cured by surgery alone in about 60% of cases.
  • To achieve this goal, we used an integrated strategy combining meta-analysis of published lung cancer microarray data with expression profiling from an experimental model.
  • The resulting 80-gene model was tested on an independent cohort of patients using RT-PCR, resulting in a 10-gene predictive model that exhibited a prognostic accuracy of approximately 75% in stage I lung adenocarcinoma when tested on 2 additional independent cohorts.
  • [MeSH-major] Adenocarcinoma. Gene Expression Regulation, Neoplastic. Lung Neoplasms. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Apr;158(4):1451-63 [11290563.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3244-50 [12036940.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Lung Cancer. 2005 Dec;50 Suppl 2:S9-16 [16557669.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1679-88 [16549822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5923-8 [16585533.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Aug;5(5):365-80 [16101384.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):3015-25 [16224537.001]
  • [Cites] Lung Cancer. 2005 Oct;50 Suppl 1:S2-4 [16291427.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):227-34 [16935391.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):293-301 [17011066.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7279-83 [17189399.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e467 [17194181.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] BMC Bioinformatics. 2006;7 Suppl 4:S8 [17217526.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2883-9 [12231532.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):226-30 [12754511.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3548-53 [12789263.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 10):19-25 [12917817.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1318-25 [14977831.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1338-43 [14977834.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):811-9 [14990636.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1157-61; discussion 1161-2 [15063225.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1555-62 [15083185.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] BMC Bioinformatics. 2004 Jun 24;5:81 [15217521.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1328-33 [7882331.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Ann Thorac Surg. 1999 Apr;67(4):927-32 [10320230.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Apr;15(4):438-43 [10371118.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4204-7 [10485455.001]
  • [Cites] EMBO J. 2004 Dec 8;23(24):4709-16 [15538380.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):183-92 [15639717.001]
  • [Cites] Lung Cancer. 2004 Dec;46 Suppl 2:S33-9 [15698530.001]
  • [Cites] Lancet Oncol. 2005 Mar;6(3):182-4 [15759364.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3198-204 [15867213.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):159-70 [15892617.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3974-86 [15930332.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):3017-24 [15840707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7 [11416219.001]
  • (PMID = 17948124.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2030461
  •  go-up   go-down


24. Minai OA, Shah S, Mazzone P, Budev MM, Sahoo D, Murthy S, Mason D, Pettersson G, Mehta AC: Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol; 2008 Dec;3(12):1404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchogenic carcinoma after lung transplantation: characteristics and outcomes.
  • BACKGROUND: Lung cancer may occur in the lung transplant population because many patients are former smokers.
  • METHODS: We performed a search of the lung transplant database at our institution to identify patients who had been diagnosed with lung cancer.
  • Records and reports were reviewed for demographics, risk factors for malignancy, lung transplant characteristics, radiographic characteristics, treatment, and outcomes.
  • RESULTS: We identified 12 lung transplant patients with bronchogenic carcinoma at our institution [age 47.2 +/- 13.2 years (mean +/- SD); 7 (58%) men and 5 (42%) women].
  • Eleven cancers occurred in the native lung; most common cancer cell types were adenocarcinoma (N = 5).
  • Incidence among patients with COPD, who received single lung transplantation was 5.15%.
  • CONCLUSIONS: Among our patients, almost all cancers occurred in native lung in ex-smokers who received a lung transplant for COPD.
  • The cancer was often an incidental finding on a routine chest radiograph; however, the disease was usually at an advanced stage at diagnosis, limiting therapeutic options.
  • [MeSH-major] Carcinoma, Bronchogenic / etiology. Lung Neoplasms / etiology. Lung Transplantation / adverse effects. Pulmonary Disease, Chronic Obstructive / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2008 Dec;3(12):1377-8 [19057259.001]
  • (PMID = 19057264.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hanagiri T, Baba T, Ichiki Y, Yasuda M, Sugaya M, Ono K, Uramoto H, Takenoyama M, Yasumoto K: Sleeve lobectomy for patients with non-small cell lung cancer. Int J Surg; 2010;8(1):39-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleeve lobectomy for patients with non-small cell lung cancer.
  • PURPOSE: A sleeve lobectomy for lung cancer is a procedure intended both for the maintenance of lung function and for radical treatment.
  • We investigated the clinico-pathological features and treatment responses of lung cancer patients who underwent sleeve lobectomy in our department.
  • SUBJECTS: Among the 984 patients with non-small cell lung cancer who underwent resection in our department between 1994 and 2007, the subjects were 24 patients in whom a sleeve lobectomy was performed.
  • The histological type was diagnosed as squamous cell carcinoma in 14 patients, and adenocarcinoma in 10.
  • The pathological stage was evaluated as IA, IB, II, IIIA, IIIB, and IV in 4, 1, 8, 8, 2, and 1 patient, respectively.
  • The 5-year survival rates in squamous cell carcinoma and adenocarcinoma were 83.0% and 45.7%, respectively.
  • CONCLUSION: Sleeve lobectomy facilitated the maintenance of residual lung function without serious perioperative complications.
  • This finding suggests that patients with direct tumor invasion to the bronchus might be good candidates for a sleeve lobectomy, but not those with extra-nodal invasion.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19850158.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Deesomchok A, Dechayonbancha N, Thongprasert S: Lung cancer in Maharaj Nakorn Chiang Mai Hospital: comparison of the clinical manifestations between the young and old age groups. J Med Assoc Thai; 2005 Sep;88(9):1236-41
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in Maharaj Nakorn Chiang Mai Hospital: comparison of the clinical manifestations between the young and old age groups.
  • OBJECTIVES: To examine and compare the clinical manifestations of lung cancer between the age groups of 40 years or less and over 40 years at Maharaj Nakorn Chiang Mai Hospital from January 2002 - December 2003.
  • MATERIAL AND METHOD: Six hundred and nineteen patients with confirmed pathological cell type lung cancer were newly registered.
  • Mass or nodule was the most common radiographic finding, and adenocarcinoma was the most common pathological cell type.
  • Most of the patients (82.4%) presented in the advanced stage.
  • In this group, chest pain and adenocarcinoma were presented more significantly, while a smoking history was found to be less significant in females.
  • More than 80% of both patient groups presented in the advanced stage.
  • CONCLUSION: Lung cancer in the young is uncommon, but most clinical manifestations are not different from older patients.
  • The less significant smoking history, especially in females, tendency of shorter duration of symptoms, and more frequent adenocarcinoma in the younger patients may have some factors that are associated and should be studied further.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536110.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


27. Zell JA, Ou SH, Ziogas A, Anton-Culver H: Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol; 2005 Nov 20;23(33):8396-405
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors.
  • RESULTS: Incident cases (11,969) of non-small-cell lung cancer (NSCLC) were analyzed, including 626 cases of BAC (5.2%).
  • This survival benefit remained after adjustment for sex, smoking status, and stage at presentation (hazard ratio for time of diagnosis before May 1999 compared with a diagnosis after May 1999 = 1.43; P = .015).
  • CONCLUSION: This epidemiologic study is the first to demonstrate a survival advantage for BAC patients diagnosed after May 1999 compared with BAC patients diagnosed before this time-a finding that persists after adjustment for sex, smoking status, and stage at presentation.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Lung Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Apr 20;24(12):1963; author reply 1963-4 [16622278.001]
  • (PMID = 16293870.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Okamoto J, Onda M, Hirata T, Miyamoto S, Akaishi J, Mikami I, Hirai K, Haraguchi S, Koizumi K, Shimizu K: Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women. Gend Med; 2006 Sep;3(3):223-35
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women.
  • BACKGROUND: Although clinical differences in lung cancer between men and women have been noted, few studies have examined the sex dissimilarity using gene expression analysis.
  • OBJECTIVE: The purpose of this study was to determine the different molecular carcinogenic mechanisms involved in lung cancers in Japanese men and women.
  • METHODS: Patients who received surgery for stage I lung adenocarcinoma were included.
  • RESULTS: In a microarray analysis of tissue from 13 men and 6 women, 12 genes were under-expressed and 24 genes were overexpressed in lung adenocarcinoma in women compared with men.
  • CONCLUSION: Thirty-six genes that characterize lung adenocarcinoma by sex were selected.
  • This information may contribute to the development of novel diagnostic techniques and treatment modalities that consider sex differences in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081955.001).
  • [ISSN] 1550-8579
  • [Journal-full-title] Gender medicine
  • [ISO-abbreviation] Gend Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm
  •  go-up   go-down


29. Kawamura T, Nomura M, Tojo H, Fujii K, Hamasaki H, Mikami S, Bando Y, Kato H, Nishimura T: Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics; 2010 Apr 18;73(6):1089-99
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma.
  • We used formalin-fixed paraffin-embedded (FFPE) materials for biomarker discovery in cases of lung cancer using proteomic analysis.
  • We conducted a retrospective global proteomic study in order to characterize protein expression reflecting clinical stages of individual patients with stage I lung adenocarcinoma without lymph node involvement (n=7).
  • In addition, we studied more advanced stage IIIA with spread to lymph nodes (n=6), because the degree of lymph node involvement is the most important factor for staging.
  • More than 500 proteins were identified from IA and IIIA cases, and non-parametric statistics showed that 81 proteins correlated significantly with stage IA or IIIA.
  • [MeSH-major] Adenocarcinoma / metabolism. Computational Biology / methods. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Paraffin / chemistry. Proteomics / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19948256.001).
  • [ISSN] 1876-7737
  • [Journal-full-title] Journal of proteomics
  • [ISO-abbreviation] J Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proteome; 8002-74-2 / Paraffin
  •  go-up   go-down


30. Kashiwabara K, Saeki S, Sasaki J, Nomura M, Kohrogi H: Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer. J Thorac Oncol; 2008 Dec;3(12):1416-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined evaluation of postoperative serum levels of carcinoembryonic antigen less than or equal to 2.5 ng/ml and absence of vascular invasion may predict no recurrence of stage I adenocarcinoma lung cancer.
  • STUDY OBJECTIVES: It has been reported that high levels of serum carcinoembryonic antigen (CEA) after surgery, or the presence of vascular invasion or both, are strong indicators of postoperative recurrence in patients with non-small cell lung cancer.
  • The purpose of this study is to evaluate which kind of patients with p-stage I adenocarcinoma need adjuvant chemotherapy, using those predictors.
  • PATIENTS AND METHODS: We studied 136 patients with curatively resected p-stage I adenocarcinoma during the 7-year period of January 1, 2000 to December 31, 2006.
  • Fifteen (11%) of 136 patients had postoperative recurrence (7 p-stage IA cases and 8 p-stage IB cases).
  • CONCLUSION: Combined evaluation of postoperative CEA levels and vascular invasion makes it possible to predict disease recurrence in the curatively resected p-stage I adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Lung Neoplasms / blood. Neoplasm Recurrence, Local / diagnosis. Neovascularization, Pathologic / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057266.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


31. Oura H, Hirose M, Aikawa H, Ishiki M: [Abdominal organ infarction encountered immediately after surgery of primary lung cancer]. Kyobu Geka; 2005 Feb;58(2):137-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdominal organ infarction encountered immediately after surgery of primary lung cancer].
  • Very rare cases of abdominal organ infarction after surgery of primary lung cancer were reported.
  • Case 1: Patient 1 was a 70-year-old man who underwent left upper lobectomy and ND 2a in June 1999 based on the clinical diagnosis of stage IA lung cancer.
  • Abdominal computed tomography (CT) demonstrated a specific finding compatible with renal infarction.
  • Case 2: Patient 2 was a 70-year-old woman who underwent left upper lobectomy and ND 2a in December 2002 based on the clinical diagnosis of stage IA lung cancer.
  • [MeSH-major] Infarction / etiology. Kidney / blood supply. Lung Neoplasms / surgery. Postoperative Complications / radiography. Splenic Infarction / etiology
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Carcinoma, Large Cell / surgery. Female. Humans. Male. Radiography, Abdominal. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724477.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Yen RF, Wu YW, Pan MH, Tzen KY: Early detection of splenic metastasis of lung cancer by 18F-2-fluoro-2-deoxyglucose positron emission tomography. J Formos Med Assoc; 2005 Sep;104(9):674-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of splenic metastasis of lung cancer by 18F-2-fluoro-2-deoxyglucose positron emission tomography.
  • Diagnosis of splenic involvement by lung cancer in the early stage is helpful for introducing proper treatment.
  • We report a case of pulmonary adenocarcinoma with splenic metastasis which was first detected by 18F-2-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET).
  • Although subsequent computed tomography (CT) did not reveal any lesions in the spleen, the second and third CT scans performed 10 and 13 months later confirmed the previous PET finding of splenic metastasis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16276444.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


33. Vicidomini G, Santini M, Fiorello A, Parascandolo V, Calabrò B, Pastore V: Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer? Ann Thorac Surg; 2005 Jan;79(1):254-7; discussion 254-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?
  • BACKGROUND: In patients undergoing lung resection for non-small cell lung cancer (NSCLC), the primary TNM (tumor-regional lymph node-distant metastasis) staging system is the best prognostic factor.
  • METHODS: We enrolled 84 patients (79 men, 5 women) aged between 36 and 81 years (mean age, 64.8 years) undergoing a major lung resection for NSCLC, with no preoperative evidence of pleural effusions.
  • The lavage was positive in 7.3% in patients with early stage I disease (3/41) and 37.2% in patients with stage II/III disease.
  • CONCLUSIONS: A positive cytology finding of intraoperative pre-resectional pleural lavage could be an important prognostic factor in patients undergoing major lung resection for NSCLC.
  • However, larger series are needed to define accurately the role of this technique in early stage lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Intraoperative Care / methods. Lung Neoplasms / pathology. Pleural Cavity / cytology. Pleural Effusion, Malignant / diagnosis. Therapeutic Irrigation
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Predictive Value of Tests. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Oct;80(4):1564; author reply 1565 [16181927.001]
  • (PMID = 15620952.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mochizuki T, Kawai O, Hasebe T, Ochiai A: Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer; 2008 Dec;62(3):302-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
  • OBJECTIVES: Several trials have recently reported the efficacy of adjuvant chemotherapy for resected stage IB non-small cell lung cancer (NSCLC).
  • However, the histological findings and prognosis of stage IB lung adenocarcinoma vary considerably.
  • The aim of this study was to investigate prognostic factors of resected stage IB adenocarcinoma and identify a subgroup with a better prognosis, in which adjuvant chemotherapy could be omitted.
  • METHODS: We reviewed 413 cases of stage I lung adenocarcinoma treated by surgical resection, and investigated prognostic factors that favorably affected the survival of 106 patients with stage IB lung adenocarcinoma.
  • A subgroup with a better outcome was identified and their survival was compared with that of stage IA patients.
  • RESULTS: The 5-year survival rate of the stage IB adenocarcinoma patients was 81.7%.
  • The 5-year survival rate of the stage IB adenocarcinoma patients without pleural invasion (76 cases) was 89.3%, and it was not statistically different from that of the stage IA patients (92.7%).
  • CONCLUSIONS: The stage IB lung adenocarcinoma patients without pleural invasion had a favorable outcome that was almost the same as that of stage IA patients.
  • Because adverse effects of chemotherapy are sometimes severe and unacceptable, adjuvant chemotherapy can be omitted for stage IB adenocarcinoma without pleural invasion.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486987.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


35. López Encuentra A, Pozo Rodríguez F, Martín de Nicolás JL, Villena V, Sayas Catalán J, Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía y Torácica (GCCB-S): [Bronchioloalveolar carcinoma in Spain: a rare and different form of lung cancer]. Arch Bronconeumol; 2006 Aug;42(8):399-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bronchioloalveolar carcinoma in Spain: a rare and different form of lung cancer].
  • [Transliterated title] Carcinoma bronquioloalveolar en España. Un cáncer de pulmón infrecuente y diferente.
  • PATIENTS AND METHODS: From a total of 2,944 cases of non-small cell lung cancer (NSCLC), 82 (3%) were BAC.
  • Other characteristics showing significant differences were the higher frequency of BAC as a chance finding and the lower likelihood of weight loss or reduced performance status at the time of diagnosis.
  • Classification as stage cI was significantly more common in patients with BAC (87% vs 75%; P.001), and this difference between groups was more pronounced for stage pI (68.5% vs 47%; P< .01).
  • Only taking into account patients classified as stage pI with complete resection of NSCLC and following exclusion of operative mortality, patients with BAC presented an overall 5-year survival of 65% (95% confidence interval [CI], 51%-79%), compared with a significantly lower survival of 53% (95% CI, 50%-56%; P< .05) in patients with other forms of NSCLC.
  • CONCLUSIONS: In Spain, among cases of lung cancer treated by surgery, BAC is very rare (3%) and displays clinical characteristics that are different from other forms of NSCLC.
  • Controlling for the most basic prognostic factors (stage pI and complete resection), survival is significantly higher for BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948993.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


36. Skov BG, Fischer BM, Pappot H: Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer; 2008 Jan;59(1):88-94
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival.
  • BACKGROUND: Adenocarcinoma of the lung is more frequent in females than in males and the association with smoking is less pronounced than for the other histological subtypes of lung cancer.
  • Oestrogen induction of cell proliferation has been found in breast adenocarcinomas, and since oestrogen receptors (ER) have been demonstrated in lung tumours, a similar role of oestrogens in the development of lung cancer has been suggested.
  • There was no statistically significant correlation between ERbeta positivity and age, gender, stage, or histology.
  • After adjusting for gender, age, stage at diagnosis and histology there was no difference in survival between subjects with ERbeta positive and ERbeta negative tumours.
  • CONCLUSION: The presence of ERbeta in a tumour seems to be a positive prognostic factor for men with non-small cell lung cancer.
  • The finding confirms another recent study and suggests that the relation between oestrogens and lung cancer be investigated further.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / chemistry. Estrogen Receptor beta / analysis. Lung Neoplasms / chemistry

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905466.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


37. Thatcher N: First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc; 2008;2 Suppl 2:S3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.
  • Treatment of non-small-cell lung cancer is dependent on disease stage.
  • For patients with metastasis or locally advanced disease, the importance of finding therapeutic schemes that may benefit this population is important.
  • This review discusses therapeutic options for first- and second-line treatment in patients with advanced non-small-cell lung cancer.
  • According to current data, the combination of two cytotoxic agents is the optimum first-line treatment for patients with non-small-cell lung cancer and performance status of 0-1.
  • There are currently three drugs approved for second-line treatment of patients with advanced non-small-cell lung cancer after failure of first-line chemotherapy.
  • Analysis of data from different subgroups included in the BR.21 trial show that overall survival is similar among women and men, among patients with adenocarcinoma and epidermoid carcinoma or Asian patients compared with other ethnicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Support Oncol. 2005 Mar-Apr;3(2):149-54 [15796447.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):66-72 [9890172.001]
  • [Cites] BMJ. 1998 Sep 19;317(7161):771-5 [9740561.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1618-26 [1651993.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Aug;3(4):435-42 [12934656.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):362-72 [12618501.001]
  • [Cites] Lung Cancer. 2003 Jan;39(1):55-61 [12499095.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] Cancer Control. 2000 Nov-Dec;7(6):539-47 [11088062.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1741-54 [10974621.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Oncologist. 2008;13 Suppl 1:14-20 [18263770.001]
  • [Cites] Oncologist. 2008;13 Suppl 1:5-13 [18263769.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4743-50 [17909199.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3913-21 [17606725.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):760-6 [17228019.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):751-3 [17228017.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 [17062680.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3831-7 [16921034.001]
  • [Cites] Clin Lung Cancer. 2006 May;7(6):389-94 [16800964.001]
  • [Cites] Oncologist. 2006 Jun;11(6):655-65 [16794244.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Intern Med. 2005 Feb;44(2):107-13 [15750269.001]
  • (PMID = 18831719.001).
  • [ISSN] 1753-6561
  • [Journal-full-title] BMC proceedings
  • [ISO-abbreviation] BMC Proc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2559799
  •  go-up   go-down


38. Tham CK, Choo SP, Lim WT, Toh CK, Leong SS, Tan SH, Li HH, Tan EH: Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. J Thorac Oncol; 2009 Aug;4(8):988-93
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
  • INTRODUCTION: Randomized placebo-controlled phase III trials failed to show a survival benefit with the addition of gefitinib to platinum-based combination chemotherapy as first-line therapy in unselected patients with advanced non-small cell lung cancer (NSCLC).
  • METHODS: Never-smoker patients with chemonaive stage IIIB or IV NSCLC were treated with GCI.
  • Most patients were women, and adenocarcinoma was the most common histologic subtype.
  • A prospective randomized phase III study is needed to confirm this finding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546820.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; S65743JHBS / gefitinib
  •  go-up   go-down


39. Mino N, Miyahara R, Nakayama E, Takahashi T, Takahashi A, Iwakiri S, Sonobe M, Okubo K, Hirata T, Sehara A, Date H: A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J Surg Oncol; 2009 Sep 1;100(3):267-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma.
  • We conducted a retrospective study to determine whether the expression of the membrane type of ADAM12 (ADAM12-L) could be a prognostic factor in resected pathological (p-) stage I lung adenocarcinoma.
  • METHODS: ADAM12-L mRNA expression was quantified by a reverse-transcription polymerase chain reaction in tissue samples from 84 completely resected p-stage I lung adenocarcinoma patients.
  • CONCLUSIONS: ADAM12-L mRNA expression is an independent prognostic factor in resected p-stage I lung adenocarcinoma, and is significantly correlated with tumor differentiation stage and postoperative cancer recurrence.
  • [MeSH-major] ADAM Proteins / genetics. Adenocarcinoma / mortality. Disintegrins / genetics. Lung Neoplasms / mortality. Membrane Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544357.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Disintegrins; 0 / Membrane Proteins; 0 / RNA, Messenger; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins
  •  go-up   go-down


40. Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daurès JP: Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1119-26
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
  • INTRODUCTION: High circulating serum vascular endothelial growth factor (VEGF) levels might reflect enhanced angiogenesis in patients suffering from non-small cell lung cancer (NSCLC).
  • RESULTS: Receiver operating characteristic curves (area under the ROC curve: 0.66 +/- 0.05) showed that circulating VEGF serum level did not demonstrate a high sensitivity-specificity relationship, and therefore, demonstrated a low ability to differentiate NSCLC from benign lung diseases.
  • The circulating VEGF distribution differed significantly according to disease stage, nodal status, and performance status (PS), with the highest levels observed in metastatic stage, positive mediastinal nodal status, and poor PS.
  • CONCLUSION: The prognostic information given by a high circulating VEGF serum level is not an independent determinant of survival owing to a high relationship with main prognostic variables such as PS, stage of the disease, and nodal status.
  • This finding does not preclude a putative prognostic impact of in situ detection of VEGF and VEGF receptors in tumor specimen.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Antigens, Neoplasm / blood. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Keratin-19. Keratins / blood. Male. Middle Aged. Phosphopyruvate Hydratase / blood. Prognosis. Prospective Studies. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827607.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


41. Kim H, Chung SJ, Kim SG, Kim JS, Jung HC, Song IS: Endoscopic Ultrasonography-guided Fine Needle Aspiration for Computed Tomography-negative and Positron Emission Tomography-positive Mediastinal Lymph Node in a Patient with Recurrent Lung Cancer. Gut Liver; 2007 Jun;1(1):90-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasonography-guided Fine Needle Aspiration for Computed Tomography-negative and Positron Emission Tomography-positive Mediastinal Lymph Node in a Patient with Recurrent Lung Cancer.
  • Herein, we report a case of successful endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) for the diagnosis of CT-negative and PET-positive LN that was found after curative resection in lung cancer.
  • To the best of our knowledge, this is the first description in Korea to perform EUS-FNA for the evaluation of metastatic LN during the follow-up period after lung cancer resection.A 63-years old male patient was diagnosed as a stage T4N0M0 non-small lung cancer.
  • On PET-CT finding, a hypermetabolic lesion was noted in paraesophageal LN.
  • We performed EUS-guided FNA to obtain a biopsy specimen from paraesophageal lymph node, and this proved to be a metastatic adenocarcinoma.
  • In conclusion, EUS-FNA provided minimally invasive confirmation of the metastatic LN in recurrent a lung cancer patient after curative resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2005 Jan 15;171(2):177-82 [15502117.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):263-8 [15620955.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2090-6 [8520780.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Nov;118(5):894-9 [10534695.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):340-6 [15332020.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):628-33 [15089893.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):53-60 [15013583.001]
  • [Cites] Gastrointest Endosc. 1993 May-Jun;39(3):429-31 [8390383.001]
  • (PMID = 20485666.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871648
  • [Keywords] NOTNLM ; Endoscopic ultrasonography / Fine needle aspiration / Lung cancer / Lymph node / Metastasis
  •  go-up   go-down


42. Tanaka A, Honma K, Kondo H: [A case of cerebellum metastasis from colon cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2242-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of cerebellum metastasis from transverse colon cancer, which had no evidence of recurrence in the thoracoabdominal region by chemotherapy and resection of liver and lung metastases after initial operation.
  • The finding was moderately-differentiated adenocarcinoma, se, n1, ly1, v2, H0, P0, M0, stage IIIa.
  • Relapsing tumor, which metastasized to the liver in 3 years, the right lung in 4 years and 8 months and the left lung in 5 years and 11 months after initial operation, were totally resected.
  • Following the partial resection of the left lung, he received a treatment with 12 times of mFOLFOX6 and S-1+PSK.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037383.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Sawada S, Komori E, Nogami N, Segawa Y, Shinkai T, Yamashita M: Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. Lung Cancer; 2009 Aug;65(2):176-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 113 lung cancer patients with pure or mixed GGO findings who underwent a resection after a CT follow-up examination between 1999 and 2005 were retrospectively examined.
  • The CT findings at the initial detection, the changes in the CT findings during the CT follow-up period, the histology, the pathological stage and the outcomes after resection were reviewed and evaluated.
  • RESULTS: The CT finding at the time of the initial detection showed pure GGO in 63 patients and mixed GGO in 50 patients.
  • Histology revealed that adenocarcinoma was found in all 113 patients; squamous cell carcinoma was not found in any of the patients.
  • One-hundred twelve patients were diagnosed as having Stage IA, and a singe patient with visceral pleura invasion was diagnosed as having Stage IB.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135757.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


44. Melloni G, Doglioni C, Bandiera A, Carretta A, Ciriaco P, Arrigoni G, Zannini P: Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma. Ann Thorac Surg; 2006 Jun;81(6):2008-13
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims were to search for factors influencing prognosis and to investigate the presence of microsatellite instability in the primary tumors and the corresponding lung metastases.
  • The microsatellite instability was determined by immunohistochemical evaluation of MSH2 and MLH1 in 117 lesions (41 primary tumors and 76 lung metastases).
  • Univariate analysis showed that stage of the primary tumor (p = 0.037), radicalness of the resection (p = 0.019), and stratification into groups according to the International Registry of Lung Metastases classification (p = 0.039) were prognostic factors.
  • Multivariate analysis showed that stage of the primary tumor (p = 0.030) and the radicalness of the resection (p = 0.014) were independent prognostic factors.
  • CONCLUSIONS: Pulmonary resection of metastases from colorectal carcinoma results in long-term survival in selected patients.
  • Complete resection, stage of the primary tumor and stratification into groups according to the International Registry of Lung Metastases classification were prognostic factors.
  • This finding seems to demonstrate that pulmonary metastases are infrequent in colorectal carcinomas with microsatellite instability.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Genomic Instability. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Microsatellite Repeats. MutS Homolog 2 Protein / genetics. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. Pneumonectomy / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731121.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; U3P01618RT / Fluorouracil
  •  go-up   go-down


45. Gartner V, Fässler-Weibel P: [Vertigo as a symptom of psychosocial pain]. Wien Med Wochenschr; 2010 Jul;160(13-14):314-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vertigo in a patient with end stage lung cancer challenges the caring team.
  • Finding out what means quality of life to an individual patient leads to general ideas about human needs.
  • [MeSH-major] Adenocarcinoma / psychology. Lung Neoplasms / psychology. Palliative Care / psychology. Quality of Life / psychology. Sick Role. Somatoform Disorders / psychology. Vertigo / psychology

  • MedlinePlus Health Information. consumer health - Dizziness and Vertigo.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694758.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


46. Iwata T, Nishiyama N, Inoue K, Kawata Y, Izumi N, Tsukioka T, Shinkawa K, Suehiro S: Biphasic pulmonary blastoma: report of a case. Ann Thorac Cardiovasc Surg; 2007 Feb;13(1):40-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchoscopic curette cytology revealed class V and a suspected adenocarcinoma, although a systemic evaluation demonstrated no metastatic lesion.
  • A biphasic pulmonary blastoma was histologically diagnosed by a characteristic finding that it was mainly constituted of immature tumor tissue that had both epithelial and mesenchymal components.
  • Stage T2N0M0 disease was diagnosed, and the patient chose not to undergo postoperative adjuvant chemotherapy; he remains well without recurrence 36 months after the operation.
  • [MeSH-major] Lung Neoplasms / diagnosis. Pulmonary Blastoma / diagnosis

  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392670.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


47. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L: EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res; 2005 Sep 15;11(18):6450-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EphB2 expression was also observed in 75 tumor categories, including serous carcinoma of the endometrium (34.8%), adenocarcinoma of the esophagus (33.3%), intestinal adenocarcinoma of the stomach (30.2%), and adenocarcinoma of the small intestine (70%).
  • The occasional finding of strong EphB2 positivity in tumors without EphB2 positivity in the corresponding normal cells [adenocarcinoma of the lung (4%) and pancreas (2.2%)] suggests that deregulation of EphB2 signaling may involve up-regulation of the protein expression.
  • In colon carcinoma, loss of EphB2 expression was associated with advanced stage (P < 0.0001) and was an indicator of poor overall survival (P = 0.0098).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166419.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphB2
  •  go-up   go-down


48. Seki N, Takasu T, Sawada S, Nakata M, Nishimura R, Segawa Y, Shibakuki R, Hanafusa T, Eguchi K: Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer; 2010 Dec;70(3):329-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma.
  • METHODS: The expression of eIF4E and 4E-BP1 was semiquantitatively examined with immunohistochemical staining in 80 patients with pathological stage I invasive lung adenocarcinoma.
  • Unfavorable prognostic factors for survival were age greater than 65 years (P=0.015), pathological stage IB disease (P=0.045), high eIF4E expression (P=0.008), and low 4E-BP1 expression (P=0.007).
  • CONCLUSIONS: Both eIF4E and 4E-BP1 are potential new prognostic factors for survival and stratification in patients with pathological stage I lung adenocarcinoma.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Eukaryotic Initiation Factor-4E / metabolism. Lung Neoplasms / diagnosis. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20621385.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / EIF4EBP1 protein, human; 0 / Eukaryotic Initiation Factor-4E; 0 / Phosphoproteins
  •  go-up   go-down


49. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, Palli D, Patel AV, Riboli E, Shu XO, Rodriguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ: Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol; 2009 Aug 15;170(4):403-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This finding and the decline in risk after smoking cessation suggest that smoking has a late-stage effect on pancreatic carcinogenesis.
  • [MeSH-major] Adenocarcinoma / etiology. Pancreatic Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] Cancer. 2002 May 1;94(9):2490-501 [12015775.001]
  • [Cites] Am J Epidemiol. 2003 Feb 15;157(4):335-44 [12578804.001]
  • [Cites] Public Health Nutr. 2002 Dec;5(6B):1113-24 [12639222.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):904-14 [4050778.001]
  • [Cites] Ann Epidemiol. 1994 Jan;4(1):1-10 [8205268.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1510-6 [7932805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):15-9 [8993792.001]
  • [Cites] Control Clin Trials. 1998 Feb;19(1):61-109 [9492970.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):535-41 [10088624.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2076-83 [15886696.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):517-23 [16537710.001]
  • [Cites] Lung Cancer. 2006 Sep;53(3):375-80 [16814423.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1993-8 [17266034.001]
  • [Cites] Am J Epidemiol. 2007 Aug 15;166(4):479-89 [17548786.001]
  • [Cites] Epidemiology. 2007 Sep;18(5):639-48 [17700253.001]
  • [Cites] Br J Nutr. 2007 Nov;98(5):1006-13 [17524168.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Mar;6(3):275-82 [18328435.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):970-5 [18250081.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jul;393(4):535-45 [18193270.001]
  • [Cites] Arch Intern Med. 1996 Oct 28;156(19):2255-60 [8885826.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S [11189683.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1445-57 [12359854.001]
  • (PMID = 19561064.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA73790; United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United Kingdom / British Heart Foundation / / ; United States / CCR NIH HHS / RC / N01-RC-45035; United States / NCI NIH HHS / CA / P30 CA016087; United States / NCI NIH HHS / CN / N01-CN-25511; United States / WHI NIH HHS / WH / N01WH42129-32; United States / NCI NIH HHS / CA / N01 CN25514; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CA / R01 CA082729; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CA / R37 CA070867; United States / NIA NIH HHS / AG / 5U01AG018033; United States / WHI NIH HHS / WH / N01WH32100-2; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / N01 CN25524; United States / WHI NIH HHS / WH / N01WH32108-9; United Kingdom / Medical Research Council / / MC/ U105630924; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NIEHS NIH HHS / ES / P30 ES000260; United States / NCI NIH HHS / CA / N01 CN25513; United States / NCI NIH HHS / CA / R01 CA070867; United States / WHI NIH HHS / WH / N01WH42107-26; United States / NCI NIH HHS / CA / N01 CN75022; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / N01 CN25512; United States / NCI NIH HHS / CA / P50 CA102701; United Kingdom / Cancer Research UK / / ; United States / WHI NIH HHS / WH / N01WH32122; United States / NCI NIH HHS / CA / R01CA098661; United States / NCI NIH HHS / CA / R01CA034588; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / N01 CN25518; United States / WHI NIH HHS / WH / N01WH32105-6; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CA / R01 CA70867; United States / NCI NIH HHS / CN / N01-CN-25516; United States / WHI NIH HHS / WH / N01WH32111-13; United States / NCI NIH HHS / CA / R01 CA82729; United States / WHI NIH HHS / WH / N01WH32118-32119; United States / NCI NIH HHS / CA / N01 CN25516; United States / NCI NIH HHS / CA / N01 CN25511; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CA / R01 CA105069; United States / NCI NIH HHS / CA / N01 CN25476; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CA / CA105069; United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01 CN045165; United States / NCI NIH HHS / CA / N01 CN25522; United States / NCI NIH HHS / CA / N01 CN25515; United States / WHI NIH HHS / WH / N01WH32115; United Kingdom / Wellcome Trust / / ; United States / WHI NIH HHS / WH / N01WH44221; United States / WHI NIH HHS / WH / N01WH22110; United States / NIEHS NIH HHS / ES / ES000260; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NCI NIH HHS / CA / P30CA016087; United States / WHI NIH HHS / WH / N01WH24152; United States / NIA NIH HHS / AG / U01 AG018033; United States / NCI NIH HHS / CN / N01-CN-25522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2733861
  •  go-up   go-down


50. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst; 2007 Aug 15;99(16):1257-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
  • We examined whether the cytokine gene expression profile of noncancerous lung tissue could predict the metastatic capability of adjacent lung adenocarcinoma.
  • METHODS: We analyzed a 15-cytokine gene expression profile in noncancerous lung tissue and corresponding lung tumor tissue from 80 US lung adenocarcinoma patients using real-time quantitative reverse transcription-polymerase chain reaction.
  • We then used unsupervised hierarchical clustering and Prediction Analysis of Microarray classification to test the prognostic ability of the 15-cytokine gene profile in the US patients and in an independent validation set comprising 50 Japanese patients with stage I disease.
  • RESULTS: A 15-cytokine gene signature in noncancerous lung tissue primarily reflected the lymph node status of 80 lung adenocarcinoma patients, whereas the gene signature of the corresponding lung tumor tissue was associated with prognosis independent of lymph node status.
  • Cytokine Lung Adenocarcinoma Survival Signature of 11 genes (CLASS-11), a refined 11-gene signature, accurately classified patients, including those with stage I disease, according to risk of death from adenocarcinoma.
  • CLASS-11 prognostic classification was statistically significantly associated with survival and was an independent prognostic factor for stage I patients (hazard ratio for death in the high-risk CLASS-11 group compared with the low-risk CLASS-11 reference group = 7.46, 95% confidence interval = 2.14 to 26.05; P = .002).
  • CONCLUSION: CLASS-11, which consists of genes for pro- and anti-inflammatory cytokines, identifies stage I lung adenocarcinoma patients who have a poor prognosis.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / mortality. Cytokines / genetics. Gene Expression Profiling. Lung Neoplasms / classification. Lung Neoplasms / mortality
  • [MeSH-minor] Female. Humans. Lung / metabolism. Lung / pathology. Lymph Nodes / pathology. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686824.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down






Advertisement